JP2003504395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504395A5 JP2003504395A5 JP2001510440A JP2001510440A JP2003504395A5 JP 2003504395 A5 JP2003504395 A5 JP 2003504395A5 JP 2001510440 A JP2001510440 A JP 2001510440A JP 2001510440 A JP2001510440 A JP 2001510440A JP 2003504395 A5 JP2003504395 A5 JP 2003504395A5
- Authority
- JP
- Japan
- Prior art keywords
- lysine
- compound
- grams
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 23
- 239000004472 Lysine Substances 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 235000018977 lysine Nutrition 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- 229960003121 arginine Drugs 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000019766 L-Lysine Nutrition 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010048610 Cardiotoxicity Diseases 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 208000002682 Hyperkalemia Diseases 0.000 description 3
- 231100000259 cardiotoxicity Toxicity 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14410699P | 1999-07-16 | 1999-07-16 | |
| US60/144,106 | 1999-07-16 | ||
| PCT/EP2000/006917 WO2001005383A2 (en) | 1999-07-16 | 2000-07-17 | Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504395A JP2003504395A (ja) | 2003-02-04 |
| JP2003504395A5 true JP2003504395A5 (enExample) | 2007-09-06 |
Family
ID=22507065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001510440A Pending JP2003504395A (ja) | 1999-07-16 | 2000-07-17 | 腎臓に有害な可能性のある分子の腎臓取り込みの阻害 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1196154B1 (enExample) |
| JP (1) | JP2003504395A (enExample) |
| AU (1) | AU6275800A (enExample) |
| CA (1) | CA2379696C (enExample) |
| DE (1) | DE60030722T2 (enExample) |
| FR (1) | FR19C1073I2 (enExample) |
| WO (1) | WO2001005383A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002275059A (ja) * | 2001-03-15 | 2002-09-25 | Inst Of Physical & Chemical Res | 腎機能障害改善用アミノ酸組成物 |
| FI20010764A0 (fi) * | 2001-04-11 | 2001-04-11 | Map Medical Technologies Oy | Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen |
| EP1501535A1 (en) * | 2002-04-25 | 2005-02-02 | Recepticon ApS | Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
| WO2004084953A1 (en) * | 2003-03-24 | 2004-10-07 | Schering Ag | Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics |
| EP1462119A1 (en) * | 2003-03-24 | 2004-09-29 | Schering AG | Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics |
| JP2006199668A (ja) * | 2005-01-24 | 2006-08-03 | Hiroshima Univ | 腎毒性抑制剤として利用できる新規ペプチドおよびこれを用いた腎毒性抑制剤、並びにこれを用いた抗菌製剤 |
| EP1862172A1 (en) * | 2006-05-31 | 2007-12-05 | BioSynthema Inc. | Combination of amino acid solution and a gelatin for inhibiting renal uptake |
| EP2460542A4 (en) * | 2009-07-31 | 2015-02-18 | Riken | ENDOKRINER PANCREAS CELL INDICATOR AND ITS USE |
| RU2528414C1 (ru) * | 2013-01-25 | 2014-09-20 | Закрытое Акционерное Общество "Фарм-Синтез" | Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы |
| WO2020224780A1 (en) | 2019-05-08 | 2020-11-12 | ITM Isotopen Technologien München AG | Para-aminohippuric acid (pah) as a renal protective substance |
| IL293883A (en) * | 2019-12-14 | 2022-08-01 | Manu Chaudhary | Formulations of polybasic drugs to reduce multi-organ toxicity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69026387T2 (de) * | 1989-09-29 | 1996-11-28 | Neorx Corp., Seattle, Wash. | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten |
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| WO1997046099A1 (en) * | 1996-06-06 | 1997-12-11 | Neorx Corporation | Liver retention clearing agents |
-
2000
- 2000-07-17 CA CA002379696A patent/CA2379696C/en not_active Expired - Lifetime
- 2000-07-17 WO PCT/EP2000/006917 patent/WO2001005383A2/en not_active Ceased
- 2000-07-17 JP JP2001510440A patent/JP2003504395A/ja active Pending
- 2000-07-17 DE DE60030722T patent/DE60030722T2/de not_active Expired - Lifetime
- 2000-07-17 EP EP00949378A patent/EP1196154B1/en not_active Expired - Lifetime
- 2000-07-17 AU AU62758/00A patent/AU6275800A/en not_active Abandoned
-
2019
- 2019-12-09 FR FR19C1073C patent/FR19C1073I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1928449B1 (en) | Acetylcysteine composition and uses therefor | |
| WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
| JP2003504395A5 (enExample) | ||
| JPH06510539A (ja) | 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤 | |
| JP2005518361A5 (enExample) | ||
| WO2008009444A1 (en) | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide | |
| JPH0399012A (ja) | 経口投与可能なｎ―アセチル―システイン含有製剤 | |
| EP1196154B1 (en) | Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine | |
| CN1703214A (zh) | 改善中枢神经功能的氨基酸组合物 | |
| US8293873B2 (en) | Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take | |
| EA200501129A1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| Oshima et al. | Design, synthesis and biological evaluation of negatively charged 111In-DTPA-octreotide derivatives | |
| US20110217364A1 (en) | Conjugated suramin amino compounds for medical conditions | |
| KR101729140B1 (ko) | 쓴 맛 또는 냄새가 차폐된 아미노산 조성물 | |
| US20020198262A1 (en) | Alanine-and glycine-containing therapeutic agent for hepatitis | |
| EP0486921A1 (en) | N-acetyl-L-cysteine magnesium salt and pharmaceutical compositions containing it | |
| EP4442285A1 (en) | Stabilized radiopharmaceutical composition | |
| AU2011202871A1 (en) | Acetylcysteine composition and uses therefor | |
| HK1123972B (en) | Acetylcysteine composition and uses therefor | |
| SAHU et al. | A REVIEW ON ANALYTICAL METHODOLOGIES FOR THE DETERMINATION OF PIPERACILLIN AND TAZOBACTAM | |
| WO1998013032A1 (en) | Compositions of therapeutic agents suitable for oral administration | |
| JPWO2001052834A1 (ja) | アラニンとグリシンを含有する肝炎治療薬 |